{"success":true,"data":{"pressRelease":{"id":"136577","rtpr_id":"nPn57h34Qa-20260907","ticker":"2142","exchange":"HKEX","all_tickers":["2142"],"title":"Harbour BioMed Successfully Included in the Stock Connect, Reinforcing Capital Market Recognition","author":"PR Newswire","published_at":"2026-09-07T00:01:58.965Z","article_body":"Harbour BioMed Successfully Included in the Stock Connect, Reinforcing Capital Market Recognition\n\nPR Newswire\n\nCAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Sept. 6, 2026\n\nCAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Sept. 6, 2026\n/PRNewswire/ -- Today, shares of Harbour BioMed (the \"Company\"; HKEX:\n02142.HK) were officially included in the eligible shares list of the Stock\nConnect. Effective immediately, qualified investors in mainland China can\ndirectly invest in the Company's shares through the Shanghai-Hong Kong and\nShenzhen-Hong Kong Stock Connect programs.\n\nThis inclusion in Stock Connect marks a significant milestone, reflecting that\nthe Company's market capitalization has steadily surpassed the HK$10 billion\nthreshold, officially positioning it among the large- and mid-cap\nbiopharmaceutical companies in the Hong Kong stock market. This achievement\nunderscores the capital market's positive recognition of the Company's growth\nprospects, R&D momentum, and strategic execution, while also serving as a\nstrong testament to its long-term value being steadily acknowledged in the\nsecondary market.\n\nIn the first half of 2026, the Company recorded total revenue of approximately\nUS$122.5 million, representing a year-over-year increase of 20.9%. Adjusted\nnet profit reached approximately US$71.6 million, marking seven consecutive\nprofitable half-years and confirming that Harbour BioMed has officially\nentered a phase of \"normalized profitability,\" further validating the\nsustainability and replicability of the business model underpinning this\nplatform-based biopharmaceutical group. Cash and cash equivalents stood at\napproximately US$359.2 million as of June 30, 2026. The Company maintains\nstrong financial resources and flexibility to support its strategic execution.\n\nIn terms of the pipeline, the Company has built a portfolio of nearly 30\ndifferentiated drug candidates across multiple therapeutic areas, including\nimmunology, oncology, metabolism, and the central nervous system (CNS), with\nseveral molecules having already entered clinical trials or regulatory\nsubmission stages. Batoclimab (HBM9161), the Company's lead asset, has been\nsubmitted for Biologics License Application (BLA) review and is positioned as\na potential blockbuster therapy for multiple autoimmune indications.\nPorustobart (HBM4003), the first fully human heavy-chain-only antibody which\nentered clinical development globally, has demonstrated positive efficacy and\nsafety profiles in multiple monotherapy and combination studies targeting\nadvanced solid tumors. HBM9378, a next-generation ultra-long-acting anti-TSLP\nmonoclonal antibody, has recently achieved several key milestones. Our\npartner, Windward Bio, has initiated the Phase II SIRIUS study for HBM9378 for\nthe treatment of COPD and completed dosing of the first patients. Meanwhile,\ninitial readouts from the Phase II/III POLARIS study in asthma are expected in\nthe second half of 2026, with the first Phase III study of HBM9378 in asthma\nis expected to begin in the fourth quarter of 2026.\n\nAdditionally, continued progress on innovative molecules such as HBM7575,\nHBM7020, and LET003 underscores the Company's capabilities in target selection\nand molecular design.\n\nTo date, the Company has propelled its core pipeline into the global market\nthrough a series of out-licensing transactions. Notable examples include the\nout-licensing of ex-China rights for HBM9378 to Windward Bio; an ex-China\nlicensing agreement for HBM7020 (BCMA×CD3) with Otsuka Pharmaceutical; a\nlicense agreement and equity partnership with Solstice Oncology for HBM4003;\nand a licensing and collaboration agreement with AstraZeneca for HBM7022\n(Claudin18.2×CD3). These partnerships strongly demonstrate the Company's\nstrategic execution capabilities in unlocking the global value of its pipeline\nand accelerating clinical translation through flexible and diversified\ncollaboration models.\n\nLeveraging its industry-leading Harbour Mice(®) fully human antibody\ntechnology platform, Harbour BioMed has established itself as a leading force\nin biotech BD partnerships. Its subsidiary, Nona Biosciences, has further\nbuilt out four major technology engines—a bispecific/multispecific antibody\nplatform, an XDC platform, a CAR-T platform, and an AI-driven drug discovery\nplatform—giving it a foundational edge in the ongoing innovation wave that\nis moving the field from antibodies to antibody-plus, and from simple\nmolecules to complex modalities.\n\nTo date, the Company has entered into long-term strategic partnerships with\nleading multinational pharmaceutical companies, including AstraZeneca, Otsuka\nPharmaceutical, Bristol Myers Squibb (BMS), and Pfizer, with cumulative global\ncollaboration deal value exceeding US$13 billion. The partnership with\nAstraZeneca stands out as a particularly representative example: the\nrelationship has evolved from a single-product license into a\nmulti-dimensional framework encompassing R&D collaboration, equity\ninvestment, and a joint laboratory initiative—marking a significant value\nleap from product-level licensing to platform-level strategic partnership.\nThis collaboration serves as a benchmark paradigm for how innovative\nbiotechnology companies in China can establish deep, strategic collaborations\nwith top-tier multinational companies (MNCs).\n\nMeanwhile, the Company has been actively driving the deep integration of AI\ninto drug R&D. In October 2025, Harbour BioMed unveiled its first fully\nhuman AI HCAb generation and screening model powered by the Hu-mAtrIx™\nplatform, establishing a closed loop of \"AI design – intelligent screening\n– wet-lab validation\" that significantly enhances the efficiency and\nprecision of antibody discovery. In 2026, LET003, a next-generation\nanti-ACVR2A/2B monoclonal antibody developed using the Hu-mAtrIx™ platform,\ndelivered superior preclinical data. Subsequently, the Company entered into a\nstrategic collaboration with BioMap to co-found MegaStream TechBio,\nintegrating a proprietary ecosystem of exclusive datasets × purpose-built\nlarge models × large-scale innovative pipeline portfolio into an AI-powered\nR&D engine.\n\nThis inclusion in the Stock Connect program will further broaden the Company's\ninvestor base, attract greater participation from southbound capital,\neffectively enhance stock liquidity and market visibility, and facilitate a\nmore comprehensive discovery and recognition of the Company's value in the\ncapital markets. Besides, a more diversified investor composition will further\nstrengthen the Company's presence in the international capital markets,\nfostering a more stable and dynamic capital ecosystem to support its long-term\ngrowth.\n\nDr. Jingsong Wang, Founder, Chairman, and Chief Executive Officer of Harbour\nBioMed, commented: \"The inclusion of our shares in the Stock Connect program\nmarks an important capital markets milestone for Harbour BioMed. It strongly\nreflects the market's recognition of our business momentum, innovation\ncapabilities, and corporate governance, while also positioning us to attract\ngreater interest and support from long-term value investors. Going forward, we\nremain steadfast in our commitment to pioneering innovation, accelerating\nclinical advancement of our core pipeline, and executing on our global\npartnership strategy, as we strive to deliver strong performance that upholds\nthe trust of our shareholders.\"\n\nAbout Harbour BioMed\n\nHarbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed\nto the discovery and development of novel antibody therapeutics in immunology,\noncology and other areas. The Company is building a robust portfolio and\ndifferentiated pipeline through internal R&D capability, strategic global\ncollaborations in co-discovery and co-development, and selective acquisitions.\n\nOur proprietary antibody technology platform, Harbour Mice(®), generates\nfully human monoclonal antibodies in both the conventional two heavy and two\nlight chain (H2L2) format and the heavy chain-only (HCAb) format. Building\nupon HCAb antibodies, the HCAb-based immune cell engagers (HBICE(®))\nbispecific antibody technology enables tumor-killing effects that traditional\ncombination therapies cannot achieve. The HCAb-based Antibody Plus technology\n(HCAb PLUS™) provides comprehensive modality solutions for the development\nof innovative multi-specific medicines in different disease areas.\nAdditionally, building upon the Harbour Mice(®) platform, Harbour BioMed\nlaunched its first fully human Generative AI HCAb Model powered by its\nHu-mAtrIx™ AI platform, accelerating the development of innovative\ntherapies.\n\nBy integrating Harbour Mice(®), HBICE(®), HCAb PLUS™, a single B-cell\ncloning platform and AI technologies, Harbour BioMed has built a highly\nefficient and distinctive antibody discovery engine for developing\nnext-generation therapeutic antibodies. For more information, please\nvisit www.harbourbiomed.com (https://www.harbourbiomed.com/) .\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/harbour-biomed-successfully-included-in-the-stock-connect-reinforcing-capital-market-recognition-302870894.html\n(https://www.prnewswire.com/news-releases/harbour-biomed-successfully-included-in-the-stock-connect-reinforcing-capital-market-recognition-302870894.html)\n\nSOURCE Harbour BioMed\n\n\n\nMaKathy, kathy.ma@harbourbiomed.com, 13681792070, +86-13681792070\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1199639/HB-Logo.jpg?id=OA2930205\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn57h34Qa-20260907","title":"Harbour BioMed Successfully Included in the Stock Connect, Reinforcing Capital Market Recognition","author":"PR Newswire","ticker":"2142","created":"2026-09-07T00:01:58.965Z","tickers":["2142"],"exchange":"HKEX","article_body":"Harbour BioMed Successfully Included in the Stock Connect, Reinforcing Capital Market Recognition\n\nPR Newswire\n\nCAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Sept. 6, 2026\n\nCAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Sept. 6, 2026\n/PRNewswire/ -- Today, shares of Harbour BioMed (the \"Company\"; HKEX:\n02142.HK) were officially included in the eligible shares list of the Stock\nConnect. Effective immediately, qualified investors in mainland China can\ndirectly invest in the Company's shares through the Shanghai-Hong Kong and\nShenzhen-Hong Kong Stock Connect programs.\n\nThis inclusion in Stock Connect marks a significant milestone, reflecting that\nthe Company's market capitalization has steadily surpassed the HK$10 billion\nthreshold, officially positioning it among the large- and mid-cap\nbiopharmaceutical companies in the Hong Kong stock market. This achievement\nunderscores the capital market's positive recognition of the Company's growth\nprospects, R&D momentum, and strategic execution, while also serving as a\nstrong testament to its long-term value being steadily acknowledged in the\nsecondary market.\n\nIn the first half of 2026, the Company recorded total revenue of approximately\nUS$122.5 million, representing a year-over-year increase of 20.9%. Adjusted\nnet profit reached approximately US$71.6 million, marking seven consecutive\nprofitable half-years and confirming that Harbour BioMed has officially\nentered a phase of \"normalized profitability,\" further validating the\nsustainability and replicability of the business model underpinning this\nplatform-based biopharmaceutical group. Cash and cash equivalents stood at\napproximately US$359.2 million as of June 30, 2026. The Company maintains\nstrong financial resources and flexibility to support its strategic execution.\n\nIn terms of the pipeline, the Company has built a portfolio of nearly 30\ndifferentiated drug candidates across multiple therapeutic areas, including\nimmunology, oncology, metabolism, and the central nervous system (CNS), with\nseveral molecules having already entered clinical trials or regulatory\nsubmission stages. Batoclimab (HBM9161), the Company's lead asset, has been\nsubmitted for Biologics License Application (BLA) review and is positioned as\na potential blockbuster therapy for multiple autoimmune indications.\nPorustobart (HBM4003), the first fully human heavy-chain-only antibody which\nentered clinical development globally, has demonstrated positive efficacy and\nsafety profiles in multiple monotherapy and combination studies targeting\nadvanced solid tumors. HBM9378, a next-generation ultra-long-acting anti-TSLP\nmonoclonal antibody, has recently achieved several key milestones. Our\npartner, Windward Bio, has initiated the Phase II SIRIUS study for HBM9378 for\nthe treatment of COPD and completed dosing of the first patients. Meanwhile,\ninitial readouts from the Phase II/III POLARIS study in asthma are expected in\nthe second half of 2026, with the first Phase III study of HBM9378 in asthma\nis expected to begin in the fourth quarter of 2026.\n\nAdditionally, continued progress on innovative molecules such as HBM7575,\nHBM7020, and LET003 underscores the Company's capabilities in target selection\nand molecular design.\n\nTo date, the Company has propelled its core pipeline into the global market\nthrough a series of out-licensing transactions. Notable examples include the\nout-licensing of ex-China rights for HBM9378 to Windward Bio; an ex-China\nlicensing agreement for HBM7020 (BCMA×CD3) with Otsuka Pharmaceutical; a\nlicense agreement and equity partnership with Solstice Oncology for HBM4003;\nand a licensing and collaboration agreement with AstraZeneca for HBM7022\n(Claudin18.2×CD3). These partnerships strongly demonstrate the Company's\nstrategic execution capabilities in unlocking the global value of its pipeline\nand accelerating clinical translation through flexible and diversified\ncollaboration models.\n\nLeveraging its industry-leading Harbour Mice(®) fully human antibody\ntechnology platform, Harbour BioMed has established itself as a leading force\nin biotech BD partnerships. Its subsidiary, Nona Biosciences, has further\nbuilt out four major technology engines—a bispecific/multispecific antibody\nplatform, an XDC platform, a CAR-T platform, and an AI-driven drug discovery\nplatform—giving it a foundational edge in the ongoing innovation wave that\nis moving the field from antibodies to antibody-plus, and from simple\nmolecules to complex modalities.\n\nTo date, the Company has entered into long-term strategic partnerships with\nleading multinational pharmaceutical companies, including AstraZeneca, Otsuka\nPharmaceutical, Bristol Myers Squibb (BMS), and Pfizer, with cumulative global\ncollaboration deal value exceeding US$13 billion. The partnership with\nAstraZeneca stands out as a particularly representative example: the\nrelationship has evolved from a single-product license into a\nmulti-dimensional framework encompassing R&D collaboration, equity\ninvestment, and a joint laboratory initiative—marking a significant value\nleap from product-level licensing to platform-level strategic partnership.\nThis collaboration serves as a benchmark paradigm for how innovative\nbiotechnology companies in China can establish deep, strategic collaborations\nwith top-tier multinational companies (MNCs).\n\nMeanwhile, the Company has been actively driving the deep integration of AI\ninto drug R&D. In October 2025, Harbour BioMed unveiled its first fully\nhuman AI HCAb generation and screening model powered by the Hu-mAtrIx™\nplatform, establishing a closed loop of \"AI design – intelligent screening\n– wet-lab validation\" that significantly enhances the efficiency and\nprecision of antibody discovery. In 2026, LET003, a next-generation\nanti-ACVR2A/2B monoclonal antibody developed using the Hu-mAtrIx™ platform,\ndelivered superior preclinical data. Subsequently, the Company entered into a\nstrategic collaboration with BioMap to co-found MegaStream TechBio,\nintegrating a proprietary ecosystem of exclusive datasets × purpose-built\nlarge models × large-scale innovative pipeline portfolio into an AI-powered\nR&D engine.\n\nThis inclusion in the Stock Connect program will further broaden the Company's\ninvestor base, attract greater participation from southbound capital,\neffectively enhance stock liquidity and market visibility, and facilitate a\nmore comprehensive discovery and recognition of the Company's value in the\ncapital markets. Besides, a more diversified investor composition will further\nstrengthen the Company's presence in the international capital markets,\nfostering a more stable and dynamic capital ecosystem to support its long-term\ngrowth.\n\nDr. Jingsong Wang, Founder, Chairman, and Chief Executive Officer of Harbour\nBioMed, commented: \"The inclusion of our shares in the Stock Connect program\nmarks an important capital markets milestone for Harbour BioMed. It strongly\nreflects the market's recognition of our business momentum, innovation\ncapabilities, and corporate governance, while also positioning us to attract\ngreater interest and support from long-term value investors. Going forward, we\nremain steadfast in our commitment to pioneering innovation, accelerating\nclinical advancement of our core pipeline, and executing on our global\npartnership strategy, as we strive to deliver strong performance that upholds\nthe trust of our shareholders.\"\n\nAbout Harbour BioMed\n\nHarbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed\nto the discovery and development of novel antibody therapeutics in immunology,\noncology and other areas. The Company is building a robust portfolio and\ndifferentiated pipeline through internal R&D capability, strategic global\ncollaborations in co-discovery and co-development, and selective acquisitions.\n\nOur proprietary antibody technology platform, Harbour Mice(®), generates\nfully human monoclonal antibodies in both the conventional two heavy and two\nlight chain (H2L2) format and the heavy chain-only (HCAb) format. Building\nupon HCAb antibodies, the HCAb-based immune cell engagers (HBICE(®))\nbispecific antibody technology enables tumor-killing effects that traditional\ncombination therapies cannot achieve. The HCAb-based Antibody Plus technology\n(HCAb PLUS™) provides comprehensive modality solutions for the development\nof innovative multi-specific medicines in different disease areas.\nAdditionally, building upon the Harbour Mice(®) platform, Harbour BioMed\nlaunched its first fully human Generative AI HCAb Model powered by its\nHu-mAtrIx™ AI platform, accelerating the development of innovative\ntherapies.\n\nBy integrating Harbour Mice(®), HBICE(®), HCAb PLUS™, a single B-cell\ncloning platform and AI technologies, Harbour BioMed has built a highly\nefficient and distinctive antibody discovery engine for developing\nnext-generation therapeutic antibodies. For more information, please\nvisit www.harbourbiomed.com (https://www.harbourbiomed.com/) .\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/harbour-biomed-successfully-included-in-the-stock-connect-reinforcing-capital-market-recognition-302870894.html\n(https://www.prnewswire.com/news-releases/harbour-biomed-successfully-included-in-the-stock-connect-reinforcing-capital-market-recognition-302870894.html)\n\nSOURCE Harbour BioMed\n\n\n\nMaKathy, kathy.ma@harbourbiomed.com, 13681792070, +86-13681792070\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1199639/HB-Logo.jpg?id=OA2930205\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-09-07T00:01:59.008153138Z","server_sent_at_ms":1788739319008},"received_at":"2026-09-07T00:01:59.068Z","source_url":"https://www.prnewswire.com/news-releases/harbour-biomed-successfully-included-in-the-stock-connect-reinforcing-capital-market-recognition-302870894.html"},"analysis":{"id":"125454","press_release_id":"136577","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["capital-markets milestone release recycles previously reported H1 2026 financials as context — no new operating disclosure","issuer-authored promotional framing; sentiment drivers (liquidity, southbound flows) are indirect and unquantified"],"eventType":"other","narrative":"Harbour BioMed's shares (HKEX: 02142) were officially added to the Stock Connect eligible shares list, allowing qualified mainland China investors to buy the stock via the Shanghai-Hong Kong and Shenzhen-Hong Kong programs effective immediately.\n\nInclusion reflects the company's market capitalization surpassing the HK$10 billion threshold, positioning it among Hong Kong's large- and mid-cap biopharmaceutical names and opening the shares to southbound flows.\n\nThe release recaps H1 2026 financials as context: revenue of approximately US$122.5 million, up 20.9% year over year, with adjusted net profit of about US$71.6 million — a seventh consecutive profitable half-year — and US$359.2 million in cash as of June 30, 2026.\n\nThe practical effect is a broader investor base, better liquidity, and higher market visibility rather than any change in fundamentals; pipeline catalysts cited include batoclimab's BLA review and Windward Bio's Phase II SIRIUS COPD study of HBM9378.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Stock Connect inclusion opens southbound mainland flows to Harbour BioMed after it cleared the HK$10 billion market-cap threshold."},"keyFigures":{"revenue":122500000,"revenueYoy":"20.9%","customDimensions":{"adjusted_net_profit":"US$71.6 million","pipeline_candidates":"nearly 30","cash_and_equivalents":"US$359.2 million","market_cap_threshold":"HK$10 billion","profitable_half_years":"seven consecutive","cumulative_collaboration_deal_value":"US$13 billion"}},"quotedText":"The inclusion of our shares in the Stock Connect program marks an important capital markets milestone for Harbour BioMed.","namedEntities":{"people":[{"name":"Dr. Jingsong Wang","role":"Founder, Chairman, and Chief Executive Officer of Harbour BioMed"}],"products":["Batoclimab (HBM9161)","Porustobart (HBM4003)","HBM9378","HBM7575","HBM7020 (BCMA×CD3)","HBM7022 (Claudin18.2×CD3)","LET003","Harbour Mice","HBICE","HCAb PLUS","Hu-mAtrIx"],"companies":[{"name":"Harbour BioMed","ticker":"02142.HK","relationship":"filer"},{"name":"Nona Biosciences","relationship":"subsidiary"},{"name":"Windward Bio","relationship":"partner"},{"name":"Otsuka Pharmaceutical","relationship":"partner"},{"name":"Solstice Oncology","relationship":"partner"},{"name":"AstraZeneca","relationship":"partner"},{"name":"Bristol Myers Squibb (BMS)","relationship":"partner"},{"name":"Pfizer","relationship":"partner"},{"name":"BioMap","relationship":"partner"},{"name":"MegaStream TechBio","relationship":"joint venture"}],"dollarAmounts":[{"amount":"US$122.5 million","context":"H1 2026 total revenue"},{"amount":"US$71.6 million","context":"H1 2026 adjusted net profit"},{"amount":"US$359.2 million","context":"cash and cash equivalents as of June 30, 2026"},{"amount":"US$13 billion","context":"cumulative global collaboration deal value"},{"amount":"HK$10 billion","context":"market capitalization threshold surpassed for Stock Connect inclusion"}]},"materialImpact":{"score":2,"reasoning":"Stock Connect inclusion broadens the investor base and improves liquidity for the HK-listed shares, a genuine but largely mechanical capital-markets eligibility event with no change to fundamentals. The H1 2026 financials in the release are a recap of previously reported results, not new disclosure."},"tickerRelevance":{"others":[],"primary":"2142"},"globalImportance":22,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap HK-listed biotech","eventGravity":"capital-markets eligibility/index inclusion","issuerAuthored":true,"liquidityImpact":"southbound access broadens investor base","householdBrandBoost":0,"retailFavoriteBoost":0,"newFinancialDisclosure":false}},"event_type":"other","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"Harbour BioMed's shares (HKEX: 02142) were officially added to the Stock Connect eligible shares list, allowing qualified mainland China investors to buy the stock via the Shanghai-Hong Kong and Shenzhen-Hong Kong programs effective immediately.\n\nInclusion reflects the company's market capitalization surpassing the HK$10 billion threshold, positioning it among Hong Kong's large- and mid-cap biopharmaceutical names and opening the shares to southbound flows.\n\nThe release recaps H1 2026 financials as context: revenue of approximately US$122.5 million, up 20.9% year over year, with adjusted net profit of about US$71.6 million — a seventh consecutive profitable half-year — and US$359.2 million in cash as of June 30, 2026.\n\nThe practical effect is a broader investor base, better liquidity, and higher market visibility rather than any change in fundamentals; pipeline catalysts cited include batoclimab's BLA review and Windward Bio's Phase II SIRIUS COPD study of HBM9378.","key_figures":{"revenue":122500000,"revenueYoy":"20.9%","customDimensions":{"adjusted_net_profit":"US$71.6 million","pipeline_candidates":"nearly 30","cash_and_equivalents":"US$359.2 million","market_cap_threshold":"HK$10 billion","profitable_half_years":"seven consecutive","cumulative_collaboration_deal_value":"US$13 billion"}},"named_entities":{"people":[{"name":"Dr. Jingsong Wang","role":"Founder, Chairman, and Chief Executive Officer of Harbour BioMed"}],"products":["Batoclimab (HBM9161)","Porustobart (HBM4003)","HBM9378","HBM7575","HBM7020 (BCMA×CD3)","HBM7022 (Claudin18.2×CD3)","LET003","Harbour Mice","HBICE","HCAb PLUS","Hu-mAtrIx"],"companies":[{"name":"Harbour BioMed","ticker":"02142.HK","relationship":"filer"},{"name":"Nona Biosciences","relationship":"subsidiary"},{"name":"Windward Bio","relationship":"partner"},{"name":"Otsuka Pharmaceutical","relationship":"partner"},{"name":"Solstice Oncology","relationship":"partner"},{"name":"AstraZeneca","relationship":"partner"},{"name":"Bristol Myers Squibb (BMS)","relationship":"partner"},{"name":"Pfizer","relationship":"partner"},{"name":"BioMap","relationship":"partner"},{"name":"MegaStream TechBio","relationship":"joint venture"}],"dollarAmounts":[{"amount":"US$122.5 million","context":"H1 2026 total revenue"},{"amount":"US$71.6 million","context":"H1 2026 adjusted net profit"},{"amount":"US$359.2 million","context":"cash and cash equivalents as of June 30, 2026"},{"amount":"US$13 billion","context":"cumulative global collaboration deal value"},{"amount":"HK$10 billion","context":"market capitalization threshold surpassed for Stock Connect inclusion"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-07T00:03:50.855Z","global_importance":22,"audience_relevance":15,"importance_components":{"tickerTier":"mid-cap HK-listed biotech","eventGravity":"capital-markets eligibility/index inclusion","issuerAuthored":true,"liquidityImpact":"southbound access broadens investor base","householdBrandBoost":0,"retailFavoriteBoost":0,"newFinancialDisclosure":false}},"durationMs":111778,"modelName":"glm-4.7"}}